Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Liabilities and Shareholders Equity (2016 - 2025)

Lipocine (LPCN) has disclosed Liabilities and Shareholders Equity for 13 consecutive years, with $16.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 22.35% year-over-year to $16.1 million, compared with a TTM value of $77.7 million through Sep 2025, down 15.75%, and an annual FY2024 reading of $22.5 million, down 2.13% over the prior year.
  • Liabilities and Shareholders Equity was $16.1 million for Q3 2025 at Lipocine, down from $18.6 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $52.5 million in Q4 2021 and bottomed at $16.1 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $32.4 million, with a median of $30.5 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 140.93% in 2021, then plummeted 38.73% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $52.5 million in 2021, then decreased by 28.47% to $37.5 million in 2022, then tumbled by 38.73% to $23.0 million in 2023, then decreased by 2.13% to $22.5 million in 2024, then fell by 28.6% to $16.1 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for LPCN at $16.1 million in Q3 2025, $18.6 million in Q2 2025, and $20.5 million in Q1 2025.